The Conscious Fund's Richard Skaife talks to Proactive London's Katie Pilbeam about the latest activities at the early stage venture capital fund which continues to seek opportunities in the psychedelics field as part of its efforts to discover new plant-based medicines.
One of their investments, Albert Labs, wants to advance psychedelic drugs as a treatment for mental health conditions in the UK. The firm moved in January to undertake a reverse takeover of ME Resource Corp (CSE:MEC) (OTC:MEEXF).
The combined company will list on the CSE under the Albert Labs name, and the public capital will help advance the psilocybin-based drug, KRN-101, as a treatment for cancer-related anxiety. Albert Labs has been incubated and received funding from The Conscious Fund (TCF).